Severe adalimumab-induced thrombocytopenia in a patient with Crohn's disease

M J Casanova; M Chaparro; S Martínez; I Vicuña; J P Gisbert

doi:10.1016/j.crohns.2012.04.001

Severe adalimumab-induced thrombocytopenia in a patient with Crohn's disease

J Crohns Colitis. 2012 Dec;6(10):1034-7. doi: 10.1016/j.crohns.2012.04.001. Epub 2012 Apr 23.

Authors

M J Casanova¹, M Chaparro, S Martínez, I Vicuña, J P Gisbert

Affiliation

¹ Gastroenterology Department, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa, Spain. [email protected]

PMID: 22534313
DOI: 10.1016/j.crohns.2012.04.001

Abstract

Crohn's disease is a chronic transmural inflammatory disorder characterized by inflammation of the intestine. Anti-TNF-α drugs are used for induction and maintenance of remission in patients with this condition. Thrombocytopenia is an uncommon side effect of treatment with anti-TNF-α drugs. We report the case of a 71-year-old woman diagnosed with Crohn's disease who developed severe adalimumab-induced thrombocytopenia and who did not respond to standard therapy for thrombocytopenia.

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Adalimumab
Aged
Anti-Inflammatory Agents / adverse effects*
Anti-Inflammatory Agents / therapeutic use
Antibodies, Monoclonal, Humanized / adverse effects*
Antibodies, Monoclonal, Humanized / therapeutic use
Crohn Disease / drug therapy*
Female
Humans
Thrombocytopenia / chemically induced*
Thrombocytopenia / therapy

Substances

Anti-Inflammatory Agents
Antibodies, Monoclonal, Humanized
Adalimumab